Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000041706 | SCV000065402 | benign | not specified | 2009-11-24 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000041706 | SCV000169764 | benign | not specified | 2011-08-12 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Prevention |
RCV000041706 | SCV000317190 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Athena Diagnostics | RCV000714157 | SCV000844840 | benign | not provided | 2018-05-24 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000714157 | SCV001156874 | benign | not provided | 2023-11-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000714157 | SCV001725647 | benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003450755 | SCV004182059 | benign | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001271130 | SCV004182060 | benign | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000714157 | SCV005287614 | benign | not provided | criteria provided, single submitter | not provided | ||
Natera, |
RCV001271130 | SCV001451981 | benign | Usher syndrome type 2A | 2020-09-16 | no assertion criteria provided | clinical testing |